Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the publication of results from the prospective PONDx study on the impact of the Oncotype DX Breast Recurrence Score® test on clinical decision-making. The results, consistent with previous international studies, confirm the test's value in the management of patients with early breast cancer by more accurately identifying patients who may or may not benefit from chemotherapy, thereby targeting treatment more effectively, improving therapeutic management and increasing physicians' confidence in treatment recommendations.
The study was conducted at eight reference centers nationwide and included 204 patients with early-stage hormone receptor-positive (ER+) and HER-2-negat... To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].Content locked
